This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
CpG-depleted adeno-associated virus (AAV) vectors for improved delivery to skeletal muscle	AAV vectors depleted of the toll-like receptor 9 (TLR9) ligand CpG could improve the success of gene therapy for musculoskeletal diseases. In mice injected intramuscularly with an AAV vector expressing a reporter gene, <i>Tlr9</i> -deficient mice had decreased AAV-associated T cell responses, T helper type 1 (Th1) cell responses and major histocompatibility complex class II (MHCII) expression compared with wild-type mice. In the animals, intramuscular injection with an AAV vector that lacked CpG motifs triggered less of an immune response than an AAV-reporter vector that contained CpG motifs. Next steps could include testing the CpG-depleted AAV vectors in dogs and nonhuman primates.	Patent and licensing status unavailable	Faust, S.M. <i>et al. J. Clin. Invest.</i> ; published online June 17, 2013; doi:10.1172/JCI68205 Contact: James M. Wilson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa. e-mail: wilsonjm@mail.med.upenn.edu
	SciBX 6(28); doi:10.1038/scibx.2013.740 Published online July 25, 2013		